- Home
- BSM vs XENE Comparison
BSM vs XENE Comparison
Compare BSM & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BSM | XENE |
|---|---|---|
| Founded | 1876 | 1996 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.4B |
| IPO Year | 2015 | 2014 |
Fundamental Metrics
Financial Performance| Metric | BSM | XENE |
|---|---|---|
| Price | $13.47 | $43.97 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 11 |
| Target Price | $13.00 | ★ $53.91 |
| AVG Volume (30 Days) | 448.4K | ★ 754.3K |
| Earning Date | 11-03-2025 | 11-03-2025 |
| Dividend Yield | ★ 9.03% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.16 | N/A |
| Revenue | ★ $412,814,000.00 | $7,500,000.00 |
| Revenue This Year | $1.33 | N/A |
| Revenue Next Year | $9.53 | N/A |
| P/E Ratio | $11.49 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.78 | $26.74 |
| 52 Week High | $15.60 | $46.60 |
Technical Indicators
Market Signals| Indicator | BSM | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 44.04 | 52.02 |
| Support Level | $13.30 | $43.41 |
| Resistance Level | $13.61 | $46.36 |
| Average True Range (ATR) | 0.28 | 1.32 |
| MACD | -0.08 | -0.11 |
| Stochastic Oscillator | 18.12 | 39.83 |
Price Performance
Historical ComparisonAbout BSM Black Stone Minerals L.P.
Black Stone Minerals LP is an oil and natural gas mineral company. It owns oil and natural gas mineral interests, which makes up the majority of its asset base. Its business is actively managing an existing portfolio of mineral and royalty assets to maximize its value and expanding asset base through acquisitions of additional mineral and royalty interests.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.